SQZ Biotechnologies Co.

NYS: SQZ

GO
/marketstate/country/us

Market open

 --Real time quotes

Jan 28, 2022, 12:30 p.m.

SQZ
/zigman2/quotes/222210446/composite

$

6.52

Change

+0.18 +2.84%

Volume

Volume 24,742

Real time quotes

/zigman2/quotes/222210446/composite

Previous close

$ 6.34

$ 6.52

Change

+0.18 +2.84%

Day low

Day high

$6.40

$6.70

Open

52 week low

52 week high

$6.29

$29.34

Open

Company Description

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ Cell Therapy Platform, which uses membrane disruption to deliver material into cells. The...

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ Cell Therapy Platform, which uses membrane disruption to deliver material into cells. The company was founded by Robert S. Langer Jr., Klavis F. Jensen, Agustin Lopez Marquez, and Armon Sharei in March 2013 and is headquartered in Watertown, MA.

Valuation

Price to Sales Ratio

34.21

Price to Book Ratio

5.65

Enterprise Value to EBITDA

-1.36

Enterprise Value to Sales

3.17

Total Debt to Enterprise Value

0.08

Efficiency

Revenue/Employee

214,265.00

Income Per Employee

-515,520.00

Receivables Turnover

9.28

Total Asset Turnover

0.11

Liquidity

Current Ratio

3.91

Quick Ratio

3.91

Cash Ratio

3.77

Profitability

Operating Margin

-243.16

Pretax Margin

-240.60

Net Margin

-240.60

Return on Assets

-26.35

Return on Equity

-54.38

Return on Total Capital

-37.10

Return on Invested Capital

-39.23

Capital Structure

Total Debt to Total Equity

37.02

Total Debt to Total Capital

27.02

Total Debt to Total Assets

20.38

Long-Term Debt to Equity

30.57

Long-Term Debt to Total Capital

22.31

Officers and Executives

Name Age Officer Since Title
Ms. Amy L. Schulman 60 2015 Chairman
Dr. Armon Sharei 32 2013 Co-Founder
Dr. Howard Bernstein 62 2015 Chief Scientific Officer
Mr. Micah Zajic 39 2020 Chief Business Officer
Mr. Richard Capasso - 2021 Chief Accounting Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/12/2022 Armon Sharei
President and CEO; Director
13,000   Derivative/Non-derivative trans. at $1.81 per share. 23,530
12/31/2021 Armon Sharei
President and CEO; Director
1,686   Award at $7.59 per share. 12,796
12/31/2021 Lawrence J. Knopf
General Counsel
454   Award at $7.59 per share. 3,445
12/22/2021 Armon Sharei
President and CEO; Director
11,049   Derivative/Non-derivative trans. at $1.81 per share. 19,998
12/13/2021 Amy L. Schulman
Director
1,850   Acquisition at $10.94 per share. 20,239
12/13/2021 Amy L. Schulman
Director
1,850   Acquisition at $10.88 per share. 20,128
02/27/2021 Armon Sharei
President and CEO; Director
8,000   Derivative/Non-derivative trans. at $1.81 per share. 14,480
01/08/2021 Armon Sharei
President and CEO; Director
2,500   Derivative/Non-derivative trans. at $1.81 per share. 4,525
11/03/2020 Polaris Growth Management LLC
Director
233,654   Acquisition at $16 per share. 3,738,464
11/03/2020 Polaris Growth Management LLC
Director
16,346   Acquisition at $16 per share. 261,536
11/03/2020 Polaris Growth Management LLC
Director
233,654   Acquisition at $16 per share. 3,738,464
11/03/2020 Polaris Growth Management LLC
Director
16,346   Acquisition at $16 per share. 261,536
11/03/2020 Temasek Holdings Pte Ltd. (Investment Management)
625,000   Acquisition at $16 per share. 10,000,000
11/03/2020 American International Group, Inc.
625,000   Acquisition at $16 per share. 10,000,000
11/03/2020 Invus Public Equities Advisors LLC
465,000   Acquisition at $16 per share. 7,440,000
11/03/2020 Polaris Growth Management LLC
Director
275,860   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 Polaris Growth Management LLC
Director
2,315,652   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 Polaris Growth Management LLC
Director
161,994   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 Polaris Growth Management LLC
Director
2,315,652   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 Polaris Growth Management LLC
Director
161,994   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 Temasek Holdings Pte Ltd. (Investment Management)
1,888,924   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 American International Group, Inc.
70,344   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 American International Group, Inc.
38,895   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 American International Group, Inc.
1,511,139   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 Invus Public Equities Advisors LLC
1,141,308   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 Klavis F. Jensen
Director
14,662   Derivative/Non-derivative trans. at $0 per share. 0
11/03/2020 Amy L. Schulman
Director
11,025   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/sqz

MarketWatch News on SQZ

  1. Serica Energy profit plunges on production, prices

    2:06 a.m. April 15, 2021

    - MarketWatch.com

  2. SQZ Biotechnologies started at buy with $38 stock price target at Stifel Nicolaus

    7:18 a.m. Nov. 24, 2020

    - Tomi Kilgore

/news/nonmarketwatch/company/us/sqz

Other News on SQZ

  1. Warning: SQZ is at high risk of performing badly

    4:26 a.m. Dec. 8, 2021

    - Seeking Alpha

  2. SQZ Biotechnologies (SQZ) Investor Presentation - Slideshow

    12:59 p.m. Nov. 19, 2021

    - Seeking Alpha

  3. SQZ Biotechnologies EPS misses by $0.22, misses on revenue

    5:16 p.m. Nov. 10, 2021

    - Seeking Alpha

  4. 10-Q: SQZ BIOTECHNOLOGIES CO

    4:39 p.m. Nov. 10, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  5. 10-Q: SQZ BIOTECHNOLOGIES CO

    3:49 p.m. Aug. 4, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  6. SQZ Biotechnologies adds to board of directors

    4:14 p.m. July 1, 2021

    - Seeking Alpha

  7. Seeking Alpha Catalyst Watch

    2:30 p.m. June 11, 2021

    - Seeking Alpha

  8. SQZ Biotechnologies (SQZ) Investor Presentation - Slideshow

    2:39 p.m. May 14, 2021

    - Seeking Alpha

  9. 10-Q: SQZ BIOTECHNOLOGIES CO

    3:33 p.m. May 11, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  10. Wall Street Breakfast: The Week Ahead

    6:01 a.m. April 25, 2021

    - Seeking Alpha

  11. SQZ Biotechnologies (SQZ) Investor Presentation - Slideshow

    2:51 p.m. April 12, 2021

    - Seeking Alpha

  12. Seeking Alpha Catalyst Watch

    12:30 p.m. April 9, 2021

    - Seeking Alpha

  13. Numenor Capital Portfolio Update #1

    12:48 p.m. April 6, 2021

    - Seeking Alpha

  14. 10-K: SQZ BIOTECHNOLOGIES CO

    5:33 a.m. March 18, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  15. Loading more headlines...

At a Glance

SQZ Biotechnologies Co.

200 Arsenal Yards Boulevard

Watertown, Massachusetts 02472

Phone

1 6177588672

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$21.00M

Net Income

$-50.52M

2020 Sales Growth

4.4%

Employees

98.00

/news/pressrelease/company/us/sqz

Press Releases on SQZ

  1. SQZ Biotechnologies to Present at Cantor Global Healthcare Conference

    3:45 p.m. Sept. 27, 2021

    - BusinessWire - BZX

  2. SQZ Biotechnologies to Present at Upcoming Health Care Conferences

    5:45 a.m. Sept. 9, 2021

    - BusinessWire - BZX

  3. Loading more headlines...
Link to MarketWatch's Slice.